Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

You could call it a public relations maneuver — Bayer Healthcare’s new website encouraging women to come to them with questions and advice about contraception instead of relying on biased bloggers or the Internet. The unbranded video features blindfolded women handling a rhino and trying to guess what it is. Awkward? Maybe. At the very least, BayerforWomen.com has captured the attention of Medical Marketing & Media. But, what makes Bayer a reliable source for women?

Read the rest of this entry »

Women who have high blood pressure should use caution when taking birth control pills because the estrogen in oral contraceptives puts them at greater risk of developing blood clots and heart problems. High blood pressure affects about 74.5 million people in the United States age 20 and older.

Read the rest of this entry »

Bayer has dropped its patent suit in Delaware against Teva Pharmaceuticals Industries Ltd., and Barr Pharmaceuticals for infringing on its multi-million-dollar-selling oral contraceptive Yaz. Bayer had filed the lawsuit claiming TVA’s generic version of Yaz, known as Gianvi, infringed on Yaz. However, Bayer says it is maintaining its patent suit against Teva and Barr in Nevada District Court.

Read the rest of this entry »

A Virginia woman has filed a lawsuit against the makers of Yaz birth control pill, claiming the oral contraceptive damaged her gallbladder and drove her to attempt suicide. Megan M. Stewart, 21, filed the 11-count complaint against Bayer Corporation last month, adding to the more than 1,000 lawsuits filed against the pharmaceutical company by women who allege they were not adequately warned of the risks involved with taking Yaz, also known as Yasmin and Ocella.

Read the rest of this entry »

Things are getting even uglier between two pharmaceutical companies whose oral contraceptives will soon go head-to-head in America. First, Bayer announced it was suing Teva Pharmaceutical Industries for prematurely pushing Gianvi, its generic version of Bayer’s blockbuster birth control pill Yaz, also known as Yasmin.

Read the rest of this entry »

An understudy for the Broadway show “Wicked” has joined a lawsuit against Bayer HealthCare, claiming the company’s best-seller birth control pill Yasmin caused her to suffer a stroke at the young age of 27. Brenda Hamilton had been on the pill two years when in May 2007 she became ill. She has since recovered.

Read the rest of this entry »

Bayer’s multimillion dollar birth control pill, Yaz, will go head-to-head with generic competition with the introduction of Teva Pharmaceutical Industries’ Gianvi. Teva was awarded a 180-day marketing exclusivity period for Gianvi by the Food and Drug Administration after being the first company to file an Abbreviated New Drug Application (ANDA). Bayer isn’t taking the news lightly. The company says it plans to sue Teva for prematurely launching the new “girl” on the block, which Bayer says they are not legally permitted to do until July 2011.

Read the rest of this entry »

As Bayer HealthCare begins defending itself against a flurry of lawsuits citing health problems over its blockbuster birth control pills Yaz and Yasmin, the drug company announced it has received approval from the Food and Drug Administration (FDA) on a new oral contraceptive. Bayer’s Natazia combines the hormones estrogen and progestin in doses that adjust four times throughout a women’s menstruation cycle. Natazia is the first birth control pill to use the four-phase dosing protocol with the added benefit of controlling irregular bleeding better than other pills.

Read the rest of this entry »

Bayer boasted a 63.1 percent increase in net income for the first quarter of 2010, but the firm’s pharmaceutical sales were a big disappointment, according to PharmaTimes. Bayer posted increases in its earnings before interest, taxes, depreciation and amortization as well as in its group turnover. However Bayer’s health care sales stayed flat while pharmaceutical revenues fell a disappointing 2.2 percent.

Read the rest of this entry »

Bayer Schering Pharma has announced it will update the label in the European market for its oral contraceptive Yasmin, a combination of ethinylestradiol and the diuretic drospirenone, also known by the brand name Yaz and the generic brand Ocella. The new label will include results of four epidemiological studies conducted by independent investigators that show the risk for venous thromboembolism, or blood clots, in Yasmin users is comparable to the risk found for women who use levonorgestrel-containing oral contraceptives.

Read the rest of this entry »